GH News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GH

Mkt Cap

$21.28B

Volume

1.85M

Next Earnings

November 4th

Loading chart

GH

GHGuardant Health, Inc. Common Stock

GH

Pay with—

Available Balance0.00

GH

Mkt Cap

$22.26B

Volume

1.85M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarZacks highlights two medical stocks with positive Earnings Surprise Prediction (ESP) figures that could beat upcoming earnings expectations. Danaher (DHR) has a +0.30% ESP with a #2 Buy rating ahead of October 21 earnings, while Guardant Health (GH) has a +13.19% ESP with a #2 Buy rating before November 5 earnings. Both stocks show potential for positive earnings surprises based on recent analyst revisions.Zacks Investment Research · Oct 15, 2026

AstraZeneca Secures FDA Nod for New Breast Cancer Therapy EtcamahThe FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant) combined with CDK4/6 inhibitors for treating HR-positive, HER2-negative advanced breast cancer. The combination reduced disease progression or death risk by 56% compared to standard treatment. The FDA also approved Guardant360 CDx diagnostic test to identify patients with ESR1 mutations eligible for this therapy.Zacks Investment Research · Sep 7, 2026

Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsightThe global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.GlobeNewswire Inc. · Aug 27, 2026

State of the Life Sciences Industry to Be Reviewed in BCC Research's 2026 Second Quarter Outlook, Spotlighting AI-Driven Discovery, Precision Oncology, and Connected Health AdoptionBCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.GlobeNewswire Inc. · Aug 25, 2026

Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, with a CAGR of 4.3%. Growth is driven by rising cancer incidence, personalized medicine adoption, advances in NGS and liquid biopsy technologies, and increased biomarker-driven diagnostics. HER2 testing leads by biomarker type (21.1% share), while breast cancer testing dominates by indication (25.1% share). North America captures 52.1% of global market revenue.GlobeNewswire Inc. · Jul 22, 2026

Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS InsiderThe global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% market share, while imaging and hospital laboratories dominate their respective segments.GlobeNewswire Inc. · Jun 19, 2026

Why Grail Could Be the Sleeper Stock Everyone's About to NoticeGrail, a leader in multi-cancer early detection (MCED) testing, could be poised for significant growth as its Galleri test shows promising clinical trial results. The company awaits FDA approval and potential insurance reimbursement, which could unlock a $50 billion market opportunity. However, the stock remains high-risk due to unprofitability and competition from larger players.The Motley Fool · Jun 8, 2026

AI-Powered Imaging Systems and Deep Learning Software Revolutionize Cancer Diagnostics Market GloballyThe global AI in cancer diagnostics market is experiencing rapid growth, projected to expand from $0.79 billion in 2025 to $0.96 billion in 2026 (20.2% CAGR), reaching $1.97 billion by 2030. Growth is driven by advancements in deep learning, AI-powered imaging systems, rising cancer prevalence, and collaborations between AI developers and medical institutions. Key developments include Lunit's $193 million acquisition of Volpara and launches of integrated AI diagnostic systems by companies like Dedalus and Ibex Medical Analytics.GlobeNewswire Inc. · Jun 5, 2026

Guardant Health Secures FDA Approval For Expanded Liquid Biopsy TestGuardant Health received FDA approval for its Guardant360 Liquid CDx test, an expanded liquid biopsy panel that is now the largest FDA-approved in its category. The test evaluates a genomic footprint 100 times wider than the previous version, combines genomic and epigenomic insights from a single blood sample, and can deliver results in as little as seven days. The approval transfers seven previously approved companion diagnostic indications from the earlier Guardant360 CDx test. Shares rose 8.81% following the announcement.Benzinga · May 20, 2026

Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsightThe global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.GlobeNewswire Inc. · May 13, 2026

to start trading

GH

GHGuardant Health, Inc. Common Stock

GH

Pay with—

Available Balance0.00

Your PositionYou don't own any GH yet.

Related Tickers

Earnings